In the context of this patient's overall health, which follow-up studies should his presenting symptom prompt?
Danish Study Suggests Cardioprotective Effects of GLP-1 Agonist and Insulin
Evidence to date is conflicting on the potential role of antihyperglycemic drugs, old and new, in cardioprotection. Results reported here add to the pool and fuel ongoing study.
Why Not Prescribe a SGLT2 Inhibitor for this Patient?
The sodium glucose cotransporter-2 inhibitors have many advantages eg, modest A1c reduction and low hypoglycemia risk. But careful patient selection is critical.
Inside Insulin: 5 Sets of Facts, Figures, and Findings
Optimizing the use of insulin for treatment of hyperglycemia in patients with diabetes is an ongoing research endeavor. Here, several recent developments you should know about.
Widespread "Yellow Bumps"
A woman with poorly controlled type 2 diabetes presented with widespread “yellow bumps" of sudden onset. What's your diagnosis?
Why is a "Medical Care Opportunity" a Waste of Time?
Those friendly reminders; you get them every day--Mrs X hasn't refilled a scrip; Mr J needs an eye exam; Ms Q may be noncompliant with her ARB. Listen, I promise I DO know what the guidelines say!
Nocturnal Hypoglycemia Risk Lower with Gla-300 than with Gla-100
This is the first in a series of studies to determine if the longer, flatter action profile of U300 insulin glargine (vs U100 glargine) will result in less hypoglycemia, and especially nocturnal events.
Menopause in Women with Diabetes: Hormonal-glycemic Storm
For nondiabetic women, menopause is an extended biological and physiological purgatory. For those with type 1 or type 2 diabetes, it's worse.
By clicking Accept, you agree to become a member of the UBM Medica Community.